Ketamine Based Anti-Depressant Being Considered by FDA
Suicide is one of the leading causes of death in the United States across most age groups. This highlights the seriousness of depression and the need for a greater number of options for treatment. A ketamine-based alternative has undergoing Phase 2 clinical trials and the results are promising.
